Orexo completes 1,080 patient REZOLV opioid study

Wednesday, September 7, 2016

Orexo has announced that the REZOLV retrospective study (Retrospective Evaluation of Zubsolv Outcomes – A Longitudinal View) has been completed as planned in August. With 1,080 patients, the study is the largest retrospective study completed in the U.S. aimed at optimizing the treatment of opioid dependence.

[Read More]